How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Current techniques for imaging prostate cancer (CT, MRI, and PET agents 18F-fluorodeoxyglucose, 11C-choline, 11C-acetate, and 18F-fluciclovine) are limited in sensitivity and specificity. PSMA PET agent 68Ga-PSMA-11 has recently been approved by the FDA. We comment on the performance of novel PSMA agent 18F-DCFPyL-PET/CT.See related article by Morris et al., p. 3674.

Keyphrases

pet ct
prostate cancer
positron emission tomography
radical prostatectomy
contrast enhanced
magnetic resonance imaging
computed tomography
high resolution
deep learning
machine learning
pet imaging
photodynamic therapy
diffusion weighted imaging
fluorescence imaging